Physician

Ioana M Hinshaw, MD

According to 2025 Medicare claims, Ioana Hinshaw, MD (NPI: 1033193180) practices hematology/oncology in the Denver-Aurora-Centennial, CO market, with the plurality of this provider's patient population coming from Arapahoe, CO. This provider's primary affiliated billing organization is ROCKY MOUNTAIN CANCER CENTERS LLP (NPI: 1518941186; TIN: 841457488) and primary practice location at 80218-1237. Hinshaw is affiliated with the Banner Network Colorado, LLC (ACO ID: A4768), participating under the MSSP model.

Hinshaw's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 709 traditional Medicare patients, billed 153,983 HCPCS/CPT codes, and received $3,757,440 in Medicare payments. The top billing code was 78815 (Nuclear medicine study from skull base to mid-thigh with ct scan). Part D data shows 1,457 prescription claims across 247 beneficiaries totaling $2,139,372 in drug costs, led by Tukysa (Tucatinib). 2022 DME data shows 12 claims. Open Payments data shows 3 records totaling $2,095. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,526,333 to $3,757,440. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,326,217 and ending at $2,139,372. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $4,390 and ending at $458.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	683	93,340	$1,526,333
2016	721	88,325	$1,788,848
2017	787	115,845	$2,025,943
2018	812	129,931	$2,482,782
2019	772	118,261	$2,402,784
2020	696	103,615	$1,981,456
2021	759	106,349	$2,669,535
2022	735	98,053	$2,598,498
2023	830	143,799	$4,506,869
2024	709	153,983	$3,757,440

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	251	2,164	$1,326,217
2016	239	1,965	$1,842,530
2017	229	1,861	$1,830,478
2018	251	1,927	$1,305,100
2019	267	1,797	$1,221,102
2020	258	1,829	$2,178,181
2021	256	2,052	$1,712,815
2022	270	1,951	$1,998,647
2023	264	1,627	$1,578,601
2024	247	1,457	$2,139,372

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	87	$15,863
2016	N/R	36	$1,368
2017	N/R	30	$1,303
2018	N/R	116	$10,694
2019	N/R	167	$16,334
2020	N/R	54	$3,991
2021	N/R	64	$19,034
2022	N/R	12	$226
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
78815	Nuclear medicine study from skull base to mid-thigh with ct scan	168	186	$1,243
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	297	738	$93
80053	Blood test, comprehensive group of blood chemicals	267	711	$10
36415	Insertion of needle into vein for collection of blood sample	282	595	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	296	840	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tukysa	Tucatinib	13	390	$318,199
Revlimid	Lenalidomide	15	420	$306,312
Calquence	Acalabrutinib Maleate	16	480	$241,338
Imbruvica	Ibrutinib	12	360	$210,718
Jakafi	Ruxolitinib Phosphate	11	330	$109,782

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$2,095	GlaxoSmithKline, LLC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ioana M. Hinshaw, MD?

Tedicare shows public-source Medicare data for Ioana M. Hinshaw, MD (NPI 1033193180), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ioana M. Hinshaw, MD have ACO affiliation data?

Ioana M. Hinshaw, MD is shown with ACO affiliation data for Banner Network Colorado, LLC (MSSP, ACO ID A4768).

What billing organization is linked to Ioana M. Hinshaw, MD?

Ioana M. Hinshaw, MD is linked to ROCKY MOUNTAIN CANCER CENTERS LLP (billing NPI 1518941186) in the available physician profile data.

Does Ioana M. Hinshaw, MD have Open Payments data?

Ioana M. Hinshaw, MD has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.